Open Nav

Daré Bioscience, Inc.

introduce DARE

  • Date:Wednesday, October 17
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. We are initially focused on the areas of contraception, vaginal health and fertility. Our first product candidate, Ovaprene™, is a monthly non-hormonal contraceptive ring that is currently in clinical studies. We founded Daré because we felt product development in women’s reproductive health is fragmented – the two ends of the development spectrum are being adequately addressed but the stages of clinical development between innovation / early clinical development and late stage development / commercialization are underserved, creating a potential opportunity for Daré to fill the gap by taking products from innovation through development.
  • Company
  • Company HQ City:San Diego
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:$20 million
  • Ticker:DARE
  • Exchange:NASDAQ
  • CEO/Top Company Official:Sabrina Johnson
  • Year Founded:2015
  • Main Therapeutic Focus:Reproductive/Sexual Health
  • Lead Product in Development :Ovaprene non-hormonal monthly contraceptive
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Our first product candidate is Ovaprene™, a clinical stage, non-hormonal vaginal contraceptive ring intended to provide protection over multiple weeks of use, require no intervention at the time of intercourse, and fill a void in today’s contraception method mix. There are 40 million women in the US alone using contraception today, and half of them prefer a short acting (meaning daily, weekly or monthly), quickly reversible method. We expect to commence enrollment in the next human study in early 2018. We are committed to developing a portfolio that expands options, improves outcomes, and enhances convenience for women across a broad spectrum of categories relating to women’s reproductive health. We are currently in discussions regarding other product candidates that meet our selection criteria.